Looking back 10 years, the rare disease space has significantly evolved with a plethora of innovative orphan drug launches and many patients gaining access to much needed treatments. We take a look at what the future may hold from a pricing & market access perspective given the continued evolution and expansion of the rare disease sector. What key aspects should manufacturers already in, or considering entering, this sector be thinking about as they develop their rare disease strategy?
Join Cécile Matthews and Bhavesh Patel for their talk titled “Rare Disease 2030: What Could We Expect For Pricing & Access?”
Sign up for the leading Orphan Drug & Rare Disease Congress here: https://buff.ly/3v3t51H